$7.87
1.25% yesterday
Nasdaq, Jul 28, 10:00 pm CET
ISIN
US78349D1072
Symbol
RXST

RxSight Inc Target price 2025 - Analyst rating & recommendation

RxSight Inc Classifications & Recommendation:

Buy
65%
Hold
24%
Sell
12%

RxSight Inc Price Target

Target Price $9.18
Price $7.87
Potential
Number of Estimates 11
11 Analysts have issued a price target RxSight Inc 2026 . The average RxSight Inc target price is $9.18. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 17 analysts: 11 Analysts recommend RxSight Inc to buy, 4 to hold and 2 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the RxSight Inc stock has an average upside potential 2026 of . Most analysts recommend the RxSight Inc stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 139.93 164.29
57.08% 17.41%
EBITDA Margin -26.31% -15.01%
53.07% 42.94%
Net Margin -19.62% -22.38%
64.04% 14.04%

13 Analysts have issued a sales forecast RxSight Inc 2025 . The average RxSight Inc sales estimate is

$164m
Unlock
. This is
10.77% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$199m 34.16%
Unlock
, the lowest is
$123m 17.09%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $140m 57.08%
2025
$164m 17.41%
Unlock
2026
$185m 12.44%
Unlock
2027
$219m 18.77%
Unlock
2028
$242m 10.23%
Unlock

12 Analysts have issued an RxSight Inc EBITDA forecast 2025. The average RxSight Inc EBITDA estimate is

$-24.7m
Unlock
. This is
26.57% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-4.4m 86.87%
Unlock
, the lowest is
$-35.3m 5.03%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-36.8m 26.28%
2025
$-24.7m 32.99%
Unlock
2026
$-10.0m 59.33%
Unlock
2027
$3.4m 133.57%
Unlock

EBITDA Margin

2024 -26.31% 53.07%
2025
-15.01% 42.94%
Unlock
2026
-5.43% 63.82%
Unlock
2027
1.54% 128.36%
Unlock

13 RxSight Inc Analysts have issued a net profit forecast 2025. The average RxSight Inc net profit estimate is

$-36.8m
Unlock
. This is
38.49% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-25.6m 3.69%
Unlock
, the lowest is
$-53.7m 102.26%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-27.5m 43.51%
2025
$-36.8m 33.90%
Unlock
2026
$-33.5m 8.95%
Unlock
2027
$-24.4m 27.21%
Unlock

Net Margin

2024 -19.62% 64.04%
2025
-22.38% 14.04%
Unlock
2026
-18.12% 19.03%
Unlock
2027
-11.11% 38.69%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -0.71 -0.91
49.65% 28.17%
P/E negative
EV/Sales 0.58

13 Analysts have issued a RxSight Inc forecast for earnings per share. The average RxSight Inc EPS is

$-0.91
Unlock
. This is
35.82% lower
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-0.63 5.97%
Unlock
, the lowest is
$-1.32 97.01%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-0.71 49.65%
2025
$-0.91 28.17%
Unlock
2026
$-0.82 9.89%
Unlock
2027
$-0.60 26.83%
Unlock
2028
$-0.19 68.33%
Unlock

P/E ratio

Current -11.90 75.84%
2025
-8.80 26.02%
Unlock
2026
-9.66 9.77%
Unlock
2027
-13.28 37.47%
Unlock

Based on analysts' sales estimates for 2025, the RxSight Inc stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 0.64 95.45%
2025
0.58 9.95%
Unlock
2026
0.51 11.05%
Unlock
2027
0.43 15.82%
Unlock
2028
0.39 9.27%
Unlock

P/S ratio

Current 2.18 86.43%
2025
1.97 9.73%
Unlock
2026
1.75 11.06%
Unlock
2027
1.48 15.81%
Unlock
2028
1.34 9.28%
Unlock

Current RxSight Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Morgan Stanley
Locked
Locked
Locked Jul 15 2025
Jefferies
Locked
Locked
Locked Jul 10 2025
Needham
Locked
Locked
Locked Jul 09 2025
B of A Securities
Locked
Locked
Locked Jul 09 2025
BTIG
Locked
Locked
Locked Jul 09 2025
Wells Fargo
Locked
Locked
Locked Jul 09 2025
Stifel
Locked
Locked
Locked Jul 09 2025
Analyst Rating Date
Locked
Morgan Stanley:
Locked
Locked
Jul 15 2025
Locked
Jefferies:
Locked
Locked
Jul 10 2025
Locked
Needham:
Locked
Locked
Jul 09 2025
Locked
B of A Securities:
Locked
Locked
Jul 09 2025
Locked
BTIG:
Locked
Locked
Jul 09 2025
Locked
Wells Fargo:
Locked
Locked
Jul 09 2025
Locked
Stifel:
Locked
Locked
Jul 09 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today